Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.

Sosne, G; Rimmer, D; Kleinman, H K; Ousler, G

Sosne, G; Rimmer, D; Kleinman, H K; Ousler, G.

Affiliation

Sosne G; Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI, United States. Electronic address: gsosne@med.wayne.edu.
Rimmer D; Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI, United States; ORA Inc., Andover, MA, United States.
Kleinman HK; George Washington University, Washington, DC, United States; NIDCR/NIH, Bethesda, MD, United States.
Ousler G; Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI, United States; ORA Inc., Andover, MA, United States.

Vitam Horm ; 102: 277-306, 2016.

Article in En | MEDLINE | ID: mdl-27450739

Subject(s)

Corneal Diseases/drug therapy; Dry Eye Syndromes/drug therapy; Thymosin/therapeutic use; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Humans; Thymosin/adverse effects; Wound Healing

Key words

Cell migration; Cornea; Dry eye; Inflammation; Neuropathic keratopathy; Ocular surface disease; Thymosin beta 4; Wound healing

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thymosin / Dry Eye Syndromes / Corneal Diseases Type of study: Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Animals / Humans Language: En Journal: Vitam Horm Year: 2016 Document type: Article

Fulltext

XML

PubMed Links

Search on Google